NRAS mutation status is an independent prognostic factor in metastatic melanoma

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer

• Publication date

  2012-08-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.26724PMID 22180178PMCID PMC3310961
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical correlates of NRAS and BRAF mutations in primary human melanoma (Clinical Cancer Research (2011) 17 (229-235))

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

  2011influential reference
• BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site

  2011cited by this paper
• Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

  2011cited by this paper
• Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis

  2011cited by this paper
• Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations.

  2010cited by this paper
• Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.

  2010cited by this paper
• Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

  2010cited by this paper
• Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma

  2009cited by this paper
• Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma

  2009cited by this paper
• Final version of 2009 AJCC melanoma staging and classification.

  2009cited by this paper
• Academic Editor: Jonathan Rees, University of Edinburgh, United Kingdom

  2007cited by this paper
• B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis

  2007cited by this paper
• Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants

  2007cited by this paper
• Somatic activation of KIT in distinct subtypes of melanoma.

  2006cited by this paper
• Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

  2006cited by this paper
• NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing

  2006cited by this paper
• Distinct sets of genetic alterations in melanoma.

  2005cited by this paper
• Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

  2001cited by this paper
• Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

  2001cited by this paper
• Cancer,Facts and Figures about.

  year unknowncited by this paper

• Unraveling the Enigma of Melanoma Brain Metastasis: New Molecular Insights and Therapeutic Directions.

  2026cites this paper
• Melanoma: Pathogenesis and Targeted Therapy

  2026cites this paper
• Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF -Altered Solid Tumors or NRAS -Mutant Melanoma

  2026cites this paper
• Insights into RAS-driven melanoma and its therapeutic implications.

  2026cites this paper
• NRASQ61K/R/L Mutant Allele Frequency in Melanoma and its Correlation With Clinicopathological Characteristics

  2025cites this paper
• Integrated analysis of molecular and clinical features associated with overall survival in melanoma patients with brain metastasis

  2025cites this paper
• Research hotspots and trends of immunotherapy and melanoma: A bibliometric analysis during 2014–2024

  2025cites this paper
• Real‐World Efficacy and Safety of MEK Inhibitor for Patients With Advanced NRAS‐Mutant Melanoma: A Single‐Center Retrospective Study in Japan

  2025cites this paper
• Oncogenic EME1 promotes tumor progression and immune modulation in human cancers with therapeutic targeting potential

  2025cites this paper
• Molecular Underpinnings of Brain Metastases

  2025cites this paper
• Testing patterns, patient and tumour characteristics and survival by NRAS and KIT genotype in melanoma.

  2025cites this paper
• Primary cilia in cancer: structures, functions, mechanisms, and therapeutic implications

  2025cites this paper
• The Role of Signaling Pathways in Melanocyte Malignant Transformation and Components of Signaling Cascades as Targets for Melanoma Therapy

  2025cites this paper
• HRAS Mutations in Head and Neck Carcinomas in Japanese Patients: Clinical Significance, Prognosis, and Therapeutic Potential

  2025cites this paper
• Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma

  2025cites this paper
• Whole‐genome CRISPR‐Cas9 knockout screens identify SHOC2 as a genetic dependency in NRAS‐mutant melanoma

  2025cites this paper
• Molecular and Genetic Markers for Malignant Melanoma: Implications for Prognosis and Therapy

  2025cites this paper
• Perioperative Treatment Strategies for Advanced Melanoma and Non-Melanoma Skin Cancers.

  2025cites this paper
• Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies

  2025cites this paper
• New Standards in the Treatment of Advanced Metastatic Melanoma: Immunotherapy and BRAF-Targeted Therapies as Emerging Paradigms.

  2025cites this paper
• Ultra-sensitive detection of melanoma NRAS mutant ctDNA based on programmable endonucleases.

  2025cites this paper
• Melanoma Management: Exploring Staging, Prognosis, and Treatment Innovations

  2024cites this paper
• Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapy

  2024cites this paper
• BRAF and NRAS Mutations and the Association with Prognosis of Acral Lentiginous and Nodular Melanomas in Indonesia

  2024cites this paper
• Diagnosing Cutaneous Melanocytic Tumors in the Molecular Era: Updates and Review of Literature

  2024influential citation
• Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response.

  2024cites this paper
• Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations

  2024cites this paper
• NRAS mutant dictates AHCYL1-governed ER calcium homeostasis for melanoma tumor growth.

  2024cites this paper
• Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma

  2024cites this paper
• Ancestry and somatic profile predict acral melanoma origin and prognosis

  2024cites this paper
• Prevention of Brain Metastases: A New Frontier

  2024influential citation
• Melanoma Brain Metastasis: Biology and Therapeutic Advances.

  2024cites this paper
• Molecular Susceptibility and Treatment Challenges in Melanoma

  2024cites this paper
• Structural characterization and AlphaFold modeling of human T cell receptor recognition of NRAS cancer neoantigens

  2024cites this paper
• Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey

  2024cites this paper
• Personalized Driver Gene Prediction Using Graph Convolutional Networks with Conditional Random Fields

  2024cites this paper
• Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistance

  2024cites this paper
• Structural characterization and AlphaFold modeling of human T cell receptor recognition of NRAS cancer neoantigens

  2024cites this paper
• Estimating the risk of brain metastasis for patients newly diagnosed with cancer

  2024cites this paper
• Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances

  2024cites this paper
• Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics

  2024cites this paper
• Clinical Potential of Misshapen/NIKs-Related Kinase (MINK) 1—A Many-Sided Element of Cell Physiology and Pathology

  2024cites this paper
• Oncogenic Potential of Replication Factor C Subunit 4: Correlations with Tumor Progression and Assessment of Potential Inhibitors

  2024cites this paper
• Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches.

  2024cites this paper
• Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis

  2024cites this paper
• ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity

  2024cites this paper
• Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma

  2024cites this paper
• Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study

  2024cites this paper
• Detection of mutations in the BRAF in patients with melanoma in routine clinical practice: Survey results

  2024cites this paper
• Role of Targeted Sequencing in Routine Diagnostics of Spitz Melanocytic Neoplasms—An Analysis of 70 Cases

  2024cites this paper
• RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

  2024cites this paper
• Paradigm of biomarkers in metastatic melanoma (Review)

  2024cites this paper
• Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial

  2024cites this paper
• Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma

  2024cites this paper
• Biological characteristics and clinical management of uveal and conjunctival melanoma

  2024cites this paper
• A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer.

  2024cites this paper
• Ultraviolet (UV) radiation: a double-edged sword in cancer development and therapy

  2024cites this paper
• The Effect of Non-Overlapping Somatic Mutations in BRAF, NRAS, NF1, or CKIT on the Incidence and Outcome of Brain Metastases during Immune Checkpoint Inhibitor Therapy of Metastatic Melanoma

  2024cites this paper
• Exploring somatic mutations in BRAF, KRAS, and NRAS as therapeutic targets in Saudi colorectal cancer patients through massive parallel sequencing and variant classification

  2024cites this paper
• ACTL6A: unraveling its prognostic impact and paving the way for targeted therapeutics in carcinogenesis

  2024cites this paper
• CD133 Stimulates Cell Proliferation via the Upregulation of Amphiregulin in Melanoma

  2024cites this paper
• Very early symptomatic metastasis pseudoprogression after stereotactic brain radiosurgery in a melanoma patient treated with BRAF/MEK inhibitors: a case report and review of the literature

  2024cites this paper
• Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field

  2023cites this paper
• Phase Ib study of anlotinib in combination with anti‐PD‐L1 antibody (TQB2450) in patients with advanced acral melanoma

  2023cites this paper
• Bioinformatics analysis of the prognostic and biological significance of RASGAP genes in breast cancer

  2023cites this paper
• Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report

  2023cites this paper
• TP53 and its Regulatory Genes as Prognosis of Cutaneous Melanoma

  2023cites this paper
• New Approaches to Targeted Therapy in Melanoma

  2023cites this paper
• RETRACTED: Expression of microRNAs and their target genes in melanomas originating from gynecologic sites

  2023cites this paper
• СТАТИСТИКА / STATISTICS

  2023cites this paper
• Outcomes in patients with BRAFV600–mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib

  2023cites this paper
• Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.

  2023cites this paper
• Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern

  2023cites this paper
• The Genomic Landscape of Melanoma and Its Therapeutic Implications

  2023cites this paper
• A BRAF mutation-associated gene risk model for predicting the prognosis of melanoma

  2023cites this paper
• Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients.

  2023cites this paper
• A pan-cancer analysis reveals CHD1L as a prognostic and immunological biomarker in several human cancers

  2023cites this paper
• Mechanism-Based Redesign of GAP to Activate Oncogenic Ras

  2023cites this paper
• Chemical probe mediated visualization of protein S-palmitoylation in patient tissue samples

  2023cites this paper
• Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG.

  2023cites this paper
• Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status

  2023cites this paper
• Synchronous triple thyroid neoplasms with unique molecular alterations: A rare case report

  2023cites this paper
• Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs

  2023cites this paper
• Multiple predictive biomarker testing in melanoma: Another challenge in identifying the optimal approach on cytological samples

  2023cites this paper
• Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma

  2023cites this paper
• Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients

  2023cites this paper
• Characterisation and outcome of RAC1 mutated melanoma.

  2023cites this paper
• Malignant Melanoma in Older Adults: Different Patient or Different Disease?

  2023influential citation
• Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer.

  2023cites this paper
• Investigation of Potential High Frequency Mutation Genes and Associated Molecular Mechanism in the Progression of Thyroid Cancer

  2023cites this paper
• Prognostic and predictive biomarkers in melanoma.

  2023cites this paper
• Computational simulations of microalgae-derived bioactive compounds as a novel inhibitor against B-Raf V600E-driven melanoma

  2023cites this paper
• Cutaneous Melanoma: A Review of Multifactorial Pathogenesis, Immunohistochemistry, and Emerging Biomarkers for Early Detection and Management

  2023cites this paper
• Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases

  2023cites this paper
• Redesigned GAP to activate oncogenic GAP

  2023cites this paper
• Successes and challenges in modeling heterogeneous BRAFV600E mutated central nervous system neoplasms

  2023cites this paper
• Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma

  2023cites this paper
• Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis

  2023cites this paper
• A Case of Dedifferentiated Melanoma With Lymph Node Metastasis Where Molecular Biological Tests Were Useful for Diagnosis

  2022cites this paper
• Decoding molecular programs in melanoma brain metastases

  2022cites this paper